GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Anixa Biosciences Inc.
The stock price of Anixa Biosciences, an oncology biotech, reflects the potential of its cancer vaccines. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Cancer women
Anixa Biosciences is a biotechnology company developing immunotherapeutic drugs and vaccines for the treatment and prevention of cancer, with a particular focus on breast cancer. We classify it as part of the "Women's Cancers" sector. The chart below shows the dynamics of this important oncology segment.
Broad Market Index - GURU.Markets
Anixa Biosciences is a biotech company developing immunotherapeutic drugs and vaccines for the treatment and prevention of cancer. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
ANIX - Daily change in the company's share price Anixa Biosciences Inc.
For Anixa Biosciences, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Cancer women
Anixa Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ANIX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Anixa Biosciences is a biotech company focused on developing vaccines and therapies against cancer, including breast cancer. Its shares are driven by news of clinical successes, and their high volatility is part of a broader trend in which scientific breakthroughs shape market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Anixa Biosciences Inc.
Anixa Biosciences' year-to-date performance tells the story of its diversified approach to cancer treatment and diagnostics. Its 12-month market cap depends on progress in its programs, including the development of a breast cancer vaccine and CAR-T therapy. Success in any of these areas could fundamentally alter its valuation.
Annual dynamics of market capitalization of the market segment - Cancer women
Anixa Biosciences, Inc. is an early-stage biotech company developing cancer vaccines and immunotherapies. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risks and enormous potential of its innovative approaches.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Anixa Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cancer treatment trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Anixa Biosciences Inc.
Anixa Biosciences is a diversified biotech company focused on oncology and vaccines. Its monthly performance is a composite of news across various programs. Progress in developing a breast cancer vaccine or its CAR-T therapy could cause significant price fluctuations.
Monthly dynamics of market capitalization of the market segment - Cancer women
Anixa Biosciences is a biotech company developing immunotherapeutic drugs and vaccines for the treatment and prevention of cancer, with a particular focus on breast and ovarian cancer. The chart below shows the dynamics of the biotech sector, where preventive oncology is one of the most promising areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Anixa Biosciences is a biotech company developing cancer vaccines and new treatments. Its shares are a pure venture bet on the success of breakthrough medical technologies. Their price is driven by news of clinical trials and has no correlation with overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Anixa Biosciences Inc.
Anixa Biosciences shares reflect progress in cancer immunotherapy on a weekly basis. The price of this biotech company, which is developing vaccines to prevent breast cancer, is reacting sharply to clinical trial data that could change the paradigm in oncology.
Weekly dynamics of market capitalization of the market segment - Cancer women
Anixa Biosciences develops therapies and vaccines for cancer, including breast cancer. This is one of the most complex and competitive areas in biotech. The chart will show whether Anixa's share price fluctuations are a reaction to news about its research or reflect the overall hopes and disappointments of investors in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Anixa Biosciences is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Anixa is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
ANIX - Market capitalization of the company Anixa Biosciences Inc.
Anixa's market capitalization chart tells the story of a diversified biotech company developing both cancer vaccines and new treatments. Its volatile dynamics reflect the market's assessment of the potential of its various research programs. Its trajectory is a narrative of the search for breakthroughs on multiple fronts in oncology.
ANIX - Share of the company's market capitalization Anixa Biosciences Inc. within the market segment - Cancer women
Anixa Biosciences is a biotech company focused on developing cancer treatments and prevention methods, particularly breast cancer. Its market cap reflects the potential of its vaccine and therapeutic programs. The chart below shows how the market views its innovative approach to fighting women's cancers.
Market capitalization of the market segment - Cancer women
Anixa Biosciences is a biotech company developing cancer prevention vaccines and new treatments. The chart below shows the overall market capitalization of this sector. Its performance reflects the enormous hopes for breakthroughs in cancer prevention, where Anixa is a pioneer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Anixa Biosciences is a biotech company developing cancer vaccines and new treatments. Its market cap reflects the hope that cancer can be prevented in the same way as infectious diseases. Its volatility reflects its enormous ambitions and the risks it takes at the cutting edge of science.
Book value capitalization of the company, segment and market as a whole
ANIX - Book value capitalization of the company Anixa Biosciences Inc.
Anixa Biosciences' book value is the capital it invests in developing innovative cancer vaccines (including breast cancer) and CAR-T therapy. This provides a tangible, scientific foundation for discovering breakthrough treatments. How has this risky biotech asset changed? The chart below shows its dynamics.
ANIX - Share of the company's book capitalization Anixa Biosciences Inc. within the market segment - Cancer women
Anixa Biosciences develops cancer vaccines and antibiotics, which requires research laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovative treatment approaches.
Market segment balance sheet capitalization - Cancer women
Anixa Biosciences is developing cancer vaccines. This is a science-intensive process where intellectual property is more important than manufacturing plants. The book value chart will show how "light" this biotech company's capital base is.
Book value of all companies included in the broad market index - GURU.Markets
Anixa Biosciences is a biotechnology company focused on cancer prevention and treatment. Its book value represents its capital used to fund clinical trials of vaccines and CAR-T therapy. The chart shows the material foundation upon which breakthrough approaches to cancer treatment are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Anixa Biosciences Inc.
Anixa Biosciences' balance sheet is capital. But the market sees it as a cancer vaccine developer. The chart shows a huge "hope factor": the premium investors are paying for its breakthrough ideas that could change oncology.
Market to book capitalization ratio in a market segment - Cancer women
Anixa Biosciences is a biotech company developing cancer vaccines and new treatments. Its value is based on the potential of its research programs. The chart shows how much investors believe in its innovative approaches to cancer prevention and treatment.
Market to book capitalization ratio for the market as a whole
Anixa Biosciences is a diversified biotech company developing a breast cancer vaccine and new treatments for ovarian cancer. Its assets are its research programs. This chart shows the overall valuation, but how does the market value a company working on breakthrough but highly risky projects in women's oncology?
Debts of the company, segment and market as a whole
ANIX - Company debts Anixa Biosciences Inc.
Anixa Biosciences, a biotech company, has a diversified yet early-stage development pipeline. This chart shows how it funds its ambitious vaccine and cell therapy projects. This strategy involves investing in several high-risk areas in hopes of a single big hit.
Market segment debts - Cancer women
Anixa Biosciences is a biotech company working on cancer vaccines (particularly breast cancer) and new treatments. This is a highly ambitious and risky field. This chart shows how the company funds its long-term and expensive clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Anixa Biosciences Inc.
Anixa Biosciences is a biotech company focused on developing vaccines and therapies for cancer, including breast cancer. This chart shows how much the company relies on debt to fund its breakthrough but risky research. It's a classic example of biotech, where debt is a bet on future scientific success.
Market segment debt to market segment book capitalization - Cancer women
Anixa Biosciences is a biotech company developing cancer vaccines and new treatments. This chart shows the overall debt burden in the oncology sector. It helps understand how early-stage R&D companies finance their breakthrough but risky research, and how Anixa manages its capital.
Debt to book value of all companies in the market
Anixa Biosciences is working on cancer vaccines and new treatments. It's an early-stage biotech company, with all its funding focused on research. The company's overall debt burden chart is irrelevant to the company's financial reality, which is entirely dependent on investors' faith in its scientific potential and is financed exclusively through equity capital.
P/E of the company, segment and market as a whole
P/E - Anixa Biosciences Inc.
For Anixa Biosciences, a company developing cancer vaccines and new treatments, this chart illustrates investor expectations. Its value is based not on profits, but on the potential of its innovative immunotherapy approaches. It's a bet on a future scientific breakthrough in cancer prevention and treatment.
P/E of the market segment - Cancer women
Immuno-oncology, where Anixa Biosciences develops cancer vaccines, is the holy grail of biotech. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Anixa's valuation is a highly speculative bet that its technology will prevent cancer, not just treat it.
P/E of the market as a whole
Anixa Biosciences, Inc. is a biotech company developing cancer treatment and prevention methods, with a particular focus on breast and ovarian cancer. The company utilizes both therapeutic and vaccine approaches. This chart, reflecting investor risk appetite, demonstrates the market's willingness to invest in breakthrough but long-term cancer research projects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Anixa Biosciences Inc.
Anixa Biosciences is a biotech company developing cancer prevention vaccines and immunotherapeutics. This chart reflects the high, yet speculative, expectations for its breakthrough programs. The trend reflects the market's assessment of the likelihood of success for its vaccines, particularly against breast cancer.
%20P%2FE%20Anixa%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Anixa-Biosciences-Inc.&v=1772648057633 "Chart of the company's future (projected) P/E Anixa Biosciences Inc.")
Future (projected) P/E of the market segment - Cancer women
Anixa Biosciences is a biotech company developing cancer vaccines (particularly breast cancer) and new treatments for infectious diseases. This chart shows profitability expectations for the oncology sector. It helps understand how highly the market values its preventative approach to cancer and other innovative programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772648057643 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
Anixa Biosciences, Inc. is a biotech company developing vaccines and therapies for the treatment and prevention of cancer, with a focus on breast and ovarian cancer. This chart shows investors' risk appetite. For a company working on breakthrough but risky projects in oncology, it reflects the market's willingness to fund long-term scientific research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648057681 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Anixa Biosciences Inc.
Anixa Biosciences, Inc. is a biotechnology company focused on developing cancer treatments and prevention methods, particularly breast cancer. The financial result illustrated in this chart is comprised of clinical trial expenses. It reflects the cost of developing innovative vaccines and therapies in oncology.
Profit of companies in the market segment - Cancer women
Anixa Biosciences is a biotech company focused on developing cancer treatments and prevention methods, particularly breast cancer. Its portfolio includes vaccines and CAR-T therapy. This chart highlights the enormous potential and risks in oncology, where the development of an effective cancer vaccine could revolutionize medicine and generate colossal profits.
Overall market profit
Anixa Biosciences is a biotech company working on cancer vaccines (particularly breast cancer) and new treatments. This is a cutting-edge and high-risk sector. For companies like Anixa, a favorable economic environment, reflected in this chart, is critical to raising capital for long-term research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Anixa Biosciences Inc.
Anixa Biosciences is a biotechnology company developing cancer vaccines and new treatments. The earnings forecast reflected here reflects analysts' bets on the success of its innovative approaches in oncology, particularly in breast cancer.
%20profit%20of%20the%20company%20Anixa%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Anixa-Biosciences-Inc.&v=1772648057785 "Graph of future (projected) profit of the company Anixa Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Cancer women
Anixa Biosciences is a biotechnology company developing immunotherapeutics and vaccines for the treatment and prevention of cancer, with a particular focus on breast cancer. This chart shows the revenue forecast for the women's cancer sector, providing context for assessing the potential of Anixa's breakthrough, yet risky, developments in this important area of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772648057847 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
Anixa Biosciences is a biotech company focused on cancer diagnostics and treatment. Its future depends on the success of clinical trials. This graph, reflecting investor risk appetite, impacts the availability of capital for funding long-term and risky projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648057902 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Anixa Biosciences Inc.
Anixa Biosciences is a biotech company developing vaccines for cancer prevention (such as breast cancer) and innovative treatments. This chart reflects the high expectations of investors. The valuation is a bet on a breakthrough in preventative oncology that could change the paradigm of cancer treatment.
P/S market segment - Cancer women
Anixa Biosciences is a biotech company developing cancer treatments and diagnostics, including vaccines to prevent breast cancer and CAR-T cell therapy. This chart shows the industry average price-to-sales ratio, reflecting investor expectations for the company's breakthrough, yet early-stage, developments.
P/S of the market as a whole
Anixa Biosciences is a biotech company developing immunotherapeutics and vaccines for the treatment and prevention of cancer, with a particular focus on breast cancer. This overall market valuation chart helps understand how the market values companies working on breakthrough but long-term projects in one of the most significant areas of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Anixa Biosciences Inc.
Anixa Biosciences is a biotechnology company developing cancer prevention vaccines and new cancer treatments. This chart shows its valuation relative to projected future sales. It reflects investor expectations for the success of its breakthrough approaches in oncology.
%20P%2FS%20Anixa%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Anixa-Biosciences-Inc.&v=1772648058076 "The graph of the company's future (projected) P/S Anixa Biosciences Inc.")
Future (projected) P/S of the market segment - Cancer women
Anixa Biosciences is a biotechnology company developing immunotherapeutics and vaccines for the treatment and prevention of cancer, with a particular focus on breast and ovarian cancer. This chart reflects investor expectations for its innovative programs and potential future revenue.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772648058142 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
Anixa Biosciences is a biotechnology company focused on developing vaccines and therapies for cancer, particularly breast cancer. Its future depends on the success of clinical trials. This general expectations chart for ANIX is not a direct driver. The demand for effective cancer treatment is enormous and is not dependent on economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648058181 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Anixa Biosciences Inc.
This chart illustrates the financial path of a biotech company. For Anixa Biosciences, which focuses on developing vaccines and cancer therapies, it reflects the partnerships and funding needed to advance its innovative approaches through clinical trials.
Sales of companies in the market segment - Cancer women
Anixa Biosciences, Inc. is a biotechnology company developing immunotherapeutic drugs and vaccines for the treatment and prevention of cancer, particularly breast cancer. This chart shows revenue in the oncology segment. The potential success of Anixa's vaccine could revolutionize cancer prevention and fundamentally change the entire sector.
Overall market sales
Anixa Biosciences is a biotechnology company developing cancer vaccines (particularly breast cancer) and new treatments. The company operates at the forefront of medical science. Its advances could radically change approaches to cancer prevention and treatment, which will have a profound impact on the entire healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Anixa Biosciences Inc.
Anixa Biosciences is a biotechnology company developing vaccines to prevent cancer (particularly breast cancer) and innovative CAR-T therapies. Future sales projections depend on the success of its breakthrough clinical programs.
%20sales%20of%20the%20company%20Anixa%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Anixa-Biosciences-Inc.&v=1772648058330 "Schedule of future (projected) sales of the company Anixa Biosciences Inc.")
Future (projected) sales of companies in the market segment - Cancer women
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies against cancer, particularly breast cancer. The forecast for the women's health and oncology sector shows a huge need. The chart reflects the high expectations for preventive and therapeutic approaches that could change the paradigm of cancer control.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772648058340 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
Anixa Biosciences is a biotechnology company developing cancer treatments and diagnostics. Its success depends on clinical trial results and regulatory approval. This overall economic activity graph does not impact treatment demand, but it is important for assessing the investment climate that influences biotech funding.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648058353 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Anixa Biosciences Inc.
Anixa Biosciences is a biotech company developing cancer vaccines and immunotherapies. Being in clinical trials, it incurs high R&D expenses. This chart illustrates the investment in its scientific platform, which is typical for innovative companies seeking breakthroughs in oncology.
Market segment marginality - Cancer women
Anixa Biosciences is a biotechnology company developing cancer vaccines (particularly breast cancer) and new treatments. Profitability is a future goal, contingent on the success of clinical trials. This metric reflects the company's investment in innovative approaches to oncology compared to other biotech companies.
Market marginality as a whole
Anixa Biosciences, Inc. is a biotech company focused on developing cancer treatments and diagnostics, particularly breast cancer. This chart reflects average returns. Compared to this, Anixa is a venture bet on a breakthrough in oncology. The company is unprofitable, and its future depends on the success of clinical trials of its vaccines and assays.
Employees in the company, segment and market as a whole
Number of employees in the company Anixa Biosciences Inc.
Anixa Biosciences is a biotechnology company focused on cancer immunotherapy and vaccine development. Its small but highly qualified team of scientists and managers leads clinical programs conducted in partnership with major research centers. Growth here will mean expanding its development pipeline.
Share of the company's employees Anixa Biosciences Inc. within the market segment - Cancer women
Anixa Biosciences is a biotechnology company developing immunotherapeutic drugs and vaccines for the treatment and prevention of cancer, with a particular focus on breast cancer. This chart illustrates its scientific focus. It reflects the percentage of immunologist and oncologist researchers working on cutting-edge therapies to combat cancer in women that Anixa attracts.
Number of employees in the market segment - Cancer women
Anixa Biosciences is a biotechnology company developing cancer vaccines and new treatments. This chart illustrates cutting-edge research in preventive oncology. The growth of the research team reflects progress in creating vaccines that can "teach" the immune system to prevent cancer, such as breast cancer.
Number of employees in the market as a whole
Anixa Biosciences, Inc. is a biotechnology company developing cancer vaccines and new treatments. Their activities are focused on research and clinical trials. This general work schedule has nothing to do with them. Their future depends solely on success in the lab and their ability to raise capital for further research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Anixa Biosciences Inc. (ANIX)
Anixa Biosciences is a biotech company developing cancer vaccines (such as breast cancer) and new treatments. This chart shows how the market values preventative medicine. The very high market capitalization per employee reflects the enormous potential of this technology, which could prevent, rather than cure, one of the most dreaded diseases.
%20of%20the%20company%20Anixa%20Biosciences%20Inc.%20(ANIX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Anixa-Biosciences-Inc.-ANIX&v=1772648058556 "Chart of market capitalization per employee (in thousands of dollars) of the company Anixa Biosciences Inc. (ANIX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
Anixa Biosciences is developing cancer vaccines and new diagnostic methods. This is a cutting-edge field of biotechnology, where all value is concentrated in intellectual property. This chart demonstrates the enormous bet investors are making on the scientific potential of a small team, which is driving the extremely high valuation per employee.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772648058563 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
Anixa Biosciences is a biotech company developing cancer therapies and vaccines. This chart reflects the company's high employee valuation, as it operates at the cutting edge of science, where a single successful drug or technology can generate billions in value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648058591 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Anixa Biosciences Inc. (ANIX)
Anixa Biosciences is an early-stage biotech company focused on vaccines (including a breast cancer vaccine) and novel cancer therapies. It's an R&D company. This metric is negative. It reflects how much the company invests in each scientist to develop these breakthrough, but highly risky, therapeutic approaches.
%20Chart%20Anixa%20Biosciences%20Inc.%20(ANIX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Anixa-Biosciences-Inc.-ANIX&v=1772648058612 "Company Profit Per Employee (in thousands of dollars) Chart Anixa Biosciences Inc. (ANIX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
Anixa Biosciences (ANIX) is a biotech company focused on treating cancer (including breast cancer) and infectious diseases. As with other R&D firms, this timeline is a long shot. Profitability is negative at the research stage. ANIX's entire value lies in its scientific team and development pipeline, which could deliver breakthrough profitability in the future.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772648058654 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
Anixa Biosciences (ANIX) is a biotech company focused on cancer treatment and prevention (including vaccines). It is a clinical-stage R&D company. Negative profit per employee is the norm. The chart shows the "cost" of a team of scientists working on a breakthrough, but not yet commercialized, technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648058671 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Anixa Biosciences Inc. (ANIX)
Anixa Biosciences is a biotechnology company developing cancer therapies and vaccines. This chart reflects its status as a clinical-stage R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its innovative approaches in oncology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Anixa-Biosciences-Inc.-ANIX&v=1772648058676 "Sales chart per company employee Anixa Biosciences Inc. (ANIX)")
Sales per employee in the market segment - Cancer women
Anixa Biosciences is a biotech company developing both cancer prevention vaccines (particularly breast cancer) and CAR-T therapy. At the R&D stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee.
Sales per employee for the market as a whole
Anixa Biosciences is a biotech company focused on developing vaccines (against breast cancer) and CAR-T therapy. It's an R&D company. This chart shows revenue per employee. Predictably, it's zero. It emphasizes that the company doesn't sell products but rather invests in lengthy and expensive clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Anixa Biosciences Inc. (ANIX)
Anixa Biosciences is a biotech company developing vaccines (including against breast cancer) and CAR-T therapy. This chart shows bearish bets. Bears are betting on an extremely high risk of failure in clinical trials. The idea of a cancer vaccine is attractive, but it has not yet proven effective, making the stock highly speculative.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Anixa-Biosciences-Inc.-ANIX&v=1772648058733 "Short Shares Chart for the Company Anixa Biosciences Inc. (ANIX)")
Shares shorted by market segment - Cancer women
Anixa Biosciences is a biotech company developing therapies and vaccines for cancer (including breast cancer). This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or funding issues.
Shares shorted by the overall market
Anixa (ANIX) is a clinical-stage biotech. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Anixa Biosciences Inc. (ANIX)
Anixa Biosciences is a clinical-stage biotech. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Anixa-Biosciences-Inc.-ANIX&v=1772648058782 "RSI 14 indicator chart for the company's stock Anixa Biosciences Inc. (ANIX)")
RSI 14 Market Segment - Cancer women
Anixa (ANIX) is a biotech company focused on female cancer. They're developing vaccines (preventatives) against breast and ovarian cancer. The Cancer (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether ANIX's growth is due to their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
For Anixa Biosciences, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ANIX (Anixa Biosciences Inc.)
Anixa Biosciences is a biotechnology company developing immunotherapies (CAR-T) and vaccines for the treatment and prevention of cancer (including breast cancer). This chart shows the average target price. Analysts' forecasts are based on clinical data, vaccine potential, and partnerships.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ANIX-Anixa-Biosciences-Inc.&v=1772648058834 "A chart showing analyst consensus forecasts for the expected stock price. ANIX (Anixa Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price ANIX (Anixa Biosciences Inc.)
Anixa is a biotech company focused on developing cancer immunotherapies and vaccines. Their key project is a potential *preventive* breast cancer vaccine. This chart shows how far the current share price differs from the "fair" value predicted by analysts. The gap reflects their view on this breakthrough R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ANIX-Anixa-Biosciences-Inc.&v=1772648058836 "A chart showing the difference between the consensus forecast and the actual stock price. ANIX (Anixa Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer women
Anixa Biosciences is a biotech company developing "cancer vaccines" (particularly breast cancer) and new CAR-T therapies. This chart reflects the general expectations of analysts in the oncology sector. It shows whether experts believe in a breakthrough in "preventive" cancer vaccines or dismiss it as science fiction.
Analysts' consensus forecast for the overall market share price
Anixa Biosciences (ANIX) is a biopharmaceutical company focused on women's cancers. They are developing vaccines (to prevent breast cancer) and new treatments for ovarian cancer. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Anixa Biosciences Inc.
Anixa Biosciences is a biotech R&D machine. They don't have a single product; they operate as an incubator, developing a portfolio of breakthrough technologies (breast cancer vaccines, CAR-T therapy) and licensing them. This chart is a pure indicator of their R&D. It doesn't reflect sales, but rather a speculative valuation of their diverse (and risky) pipeline and their ability to form partnerships.
AKIMA Market Segment Index - Cancer women
Anixa Biosciences is a biotech company focused on two areas: vaccine development (including for breast cancer) and CAR-T therapy for solid tumors. This chart shows the average oncology sector index. It helps investors assess how Anixa's performance, with its innovative approach, compares to the average.
The AKIM Index for the overall market
Anixa Biosciences is a biotech company developing cancer vaccines (breast and ovarian) and diagnostic methods. It uses a partnership model with research centers. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is important for evaluating this early research platform.
